Eterna launches research to evaluate ERNA-101

Eterna (ERNA) Therapeutics announced it will investigate the ability of its lead iMSC-based cell therapy, ERNA-101, to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research agreement with The University of Texas MD Anderson Cancer Center. ERNA-101 is Eterna’s proprietary allogenic IL-7 and IL-15-secreting induced pluripotent stem cell, iPSC, derived mesenchymal stem cells, iMSC, product candidate. “This research project is pivotal in accelerating ERNA-101’s pathway to IND submission,” said Sanjeev Luther, CEO and President of Eterna. “Through this agreement, we aim to generate the data needed to demonstrate ERNA-101’s therapeutic potential in solid tumors.”